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LocalDeliveryof Heparinat CoronaryAngioplasty
Siteawiththe InfiltratorCatheter:Enhanced
IntramuralDrugDeposition
J.F. Mitchel, C.A. Pedereen, D.B. Fram, M.A. Azrin, F.J.Kieman,
R.G. McKay. Hariforrf Hospital, University of Connecticut, Hartford, CT USA
The Infiltrator is a new local d“mg delivery device that employs extruding
“nipples” on the catheter surface for direct intramural administration of ther-
apeutic agents. Tocompare the efficiency of drug deposition of this catheter
with other delivety techniques, 3H-heparin was administered following coro-
naiy angioplasfy in 29 porcine arteries either by the Infiltrator Catheter (2,500
unit.sh = 5), systemic heparin administration (22,500 unitah = 6), the lon-
tophoresis Catheter (20,000 unitaln = 6), the Dispatch Catheter (22,500
unitsln = 6), and the Hydrogel-Coated Balloon (3000 unitah = 6). Local
delivery of fluoresceinated-heparin was also performed in an additional 16
vessels to compare patterns of intramural drug deposition.
Results: Histologic analysis demonstrated fluorescent staining of thearte-
rial media and noevidence of vessel dissection in Infiltrator-treated vessels.
For all other devices, fluorescent medial staining was seen only along dis-
section planes at sitbs of vessel disruption.
Technique Units Deposited % IntramuralDeposition
Syetemic Infusion 0.01S units 0.00007%
Iontophoresis 3,4 units 0.017”/0
DiepatchCatheter 18.3 units 0.08%
HydrogelBalloon 3.0 unite 0,1%
InfiltratorCatheter 60.0 units 2.4%
Conclusions: The Infiltrator Catheter is more efficient than systemic ad-
ministration and other local delivety devices in the intramural deposition of
hepsrin at coronaw angioplasty sites. Madial deposition of drug is achieved
with the Infiltrator without significant disruption of vessel architecture.
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m7394 LocalIntramuralDeliveryof MK-0383,aPlateletGPllb/lllaReceptorBlocker,ReducesPlatelet
Depositionat the SiteofArterialInjury
N. Liu, D. H6bert, A.V. Kaplan, G. Grant, J.Y.T.Lam. Montreal Heart
Institute, Montreal, Quebec, Canada
Platelet thrombusformation atthesiteof arterial injury plays an important role
inthebiology of arterial injury. Local activation of platelets bythe injured arlery,
and cross-linking of glycoprotein GPllb/llla on activated platelets contributes
to platelet accretion on the injured arterial surface. Whether local delivery of
MK-03S3,a non-peptide inhibitor of platelet GPllb/llla receptorcsn decrease
acute platelet deposition on the injured artery was atudiad in normal Yorkshire
pigs (n = 6) undergoing carotid arterial injuiy by balloon angioplasty (5
inflations of 30 sac at 6 atm, with 1 min interval), followed by local intramural
delivery of 10 mg of MK-0383 in the right carotid, while the left carotid was
treated locally with saline control using a LocelMad infusion sleeve. PT and
PIT were not altered after local MK-0363 administration. Autologous CP1
Isballad platelet (PLT) deposition at the site of deep arterial injury, and the
degree of angiographic vasoconstriction at the aite of endothelial denudation
immediately distal, are shown below (mean + SEM);
Carotid PLT deposition Vaaoconstriction
(x 106/cm2) (% bsaeline)
Letf (control) 66.9 + 19.1 26.6 & 7.4
Right(MK-0383) 22.1 * 6,8” 11.4 + 4.8”
*p< 0.05 vs control
Thua, local intramural MK-03S3delivery reduces platalet deposition at the
site of deep arterial injury, as well as the platelet-dependent vasoconstrictive
reaponse following balloon angioplasfy, without altering systemic PT and
PTT.This may have clinical implication by Ibcally targeting effective platelet
inhibitor drug to the injury aite.
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El7395 Reducingthe Riakof PercutaneousInterventionAfterCoronaryBypassSurgery:BeneficialEffects
of AbciximabTreatment
J.E. Tcheng, K. Anderaon, B.E. Tardiff, C.F. Cabot, A.M. Lincoff, R.M. Califf,
E.J. Topol. Duke University Medical CenteL Durham, NC, USA
Coronary intervention following bypass graft aurge~ (CABG) is associated
with high complication rates. In the EPIC and EPILOG trials, the platelet GP
llb/llla blocker abciximab (c7E3 Fab, ReoPro) was investigated in 4691 pts
of all risk strata undergoing corona~ intervention. Combining the 2 trials,
661 pts (13.5%) had undergone previoue CABG, with 223 randomized to
placebo, 95 to a single bolus of c7E3, and 343 to a bolus + 12 hr infueion
of c7E3. Meta-analysis revealed a 41.0% reduction in the composite 30 day
primary endpoint of death, myocardial infarction (Ml), and urgent intervention
with the bolus + infusion etrategy:
Death,MI,or Urgentinterventionto 30Days
m
1
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Cone/uaions:The risk of clinical complications in the post-CABG patient
treated with coronary intervention is increased; this risk cen,be reduced by
treatment with c7E3 Fab.
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1739-61Abciximab(c7E3~ab,Reopro)withReduced
HepsrinDosingDuringCoronaryIntervention:Final
Resultsof theEPILOGTrial
A.M. Lincoff, J.E. Tcheng, R.M. Califf, C.F. Cabot, D.P. Miller, J.E. Booth,
E.A. Montague, KM. Anderson, E.J, Topol. C/eve/and C/irric Foundation,
C/eve/and, Off, USA
To determine whether treatment with the platelet GP llb/llla receptor antag-
onist abciximab (Abcix) could reduce ischemic complications among all pts
undergoing coronary intervention, regardless of perceived ischemic risk, and
whether the incidence of bleeding with Abcix could be reduced by modifi-
cation of heparin dosing, 2792 pts were randomized in the EPILOG trial to:
placebo with “stendarddose” weight-adjusted heparin (Plac-Std; 100 U/kg
bolus, ACT >300 s), Abcix with “standard-dose” weight-adjusted heparin
(Abeix-Std), or Abcix with “low-dose” weight-adjusted heparin (Abcix-Low;
70 U/kg bolus, ACT z 200 s), The primary endpoint was the composite of
death, Ml (CK-MB > 3x or new Q-waves), or urgent repaat revascularization
by 30 d.
Event Rates Plac-Std* Abcix-Low* Abcix-Std P*
(%) n = 939 n = 935 n = 91S
Composite 11.7 5.2 5,4 <0,0001
Desth 0.6 0.3 0.4 NS
Ml 6.7 3.7 3.8 <O,wol
Death or Ml 9.1 3.8 4.2 <O,ooo1
Urgent Revaac 5.2 1.6 2.3 <0.001
Major Bleed 3.1 2.0 3.5 NS
Trsnsfuaion 3.9 2.4 3.8 NS
Abcix administered with reduced heparin dosing markedly reduces is-
chemic risk during coronary intervention without incremental major bleeding
risk. Complete 6-month follow-up data will also be presented.
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1740-1 I ClinicalConeeWen~aofMYocardialinfarction
FollowingBalloonAngioplaatyor Directional
CoronaryAtherectomy:AcuteandOneYearResufts
ofthe Balloonvs.OptimalAtherectomyTrial(BOAT)
D.E. Cutlip, D.S. Bairn, C. Senerchia, T. DeFeo-Fraulini, K.K.L. Ho,
M. Chauhan, N.-N. Chang, R.E. Kuntz. Beth /sree/ Hospita/, Boston, MA,
USA
Myocardial infarction (Ml) defined as elevation of creatine kinase MB isoen-
zyme (CK-MB) is a frequent occurrence following percutsneoue coronary in-
tewentiona. We examined whether post-procedural CK-MB elevations were
associated with adverse acute and one year clinical outcome, including mor-
